Abstract
Introduction: Melanocyte ferroptosis has been proven to contribute to the development of vitiligo. Tanshinone IIA (TSA), a Chinese herbal extract, has been shown to inhibit vitiligo progression. Whether TSA regulates ferroptosis in melanocytes remains unclear. Methods: Hydrogen peroxide (H2O2) was used to induce melanocytes to stimulate vitiligo cell model in vitro. Cell proliferation was examined by 5-ethynyl-2′-deoxyuridine assay. The levels of malondialdehyde, reactive oxygen species, glutathione peroxidase, and iron were detected by corresponding commercial kit. The protein levels of ferroptosis-related markers and Nrf2 pathway-related markers were examined using western blot and immunofluorescence staining. Cell viability and cytotoxicity were analyzed using Cell Counting Kit-8 assay and lactate dehydrogenase detection. Mitochondrial morphology was examined using a transmission electron microscope. Results: After H2O2 treatment, melanocyte proliferation was reduced, while oxidative stress and ferroptosis were enhanced. TSA treatment could inhibit ferroptosis in H2O2-induced melanocytes. Besides, TSA could activate Nrf2 pathway and promote Nrf2 nuclear translocation, and Nrf2-specific inhibitor (ML385) also reversed the inhibitory effect of TSA on H2O2-induced melanocyte ferroptosis. Conclusion: Our data showed that TSA alleviated H2O2-induced melanocyte ferroptosis via activating Nrf2 pathway.
Journal Section:
Research Article
References
1.
Chen
J
, Li
S
, Li
C
. Mechanisms of melanocyte death in vitiligo
. Med Res Rev
. 2021
;41
(2
):1138
–66
. 2.
Wu
X
, Yang
Y
, Xiang
L
, Zhang
C
. The fate of melanocyte: mechanisms of cell death in vitiligo
. Pigment Cell Melanoma Res
. 2021
;34
(2
):256
–67
. 3.
Wang
Y
, Li
S
, Li
C
. Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity
. Med Sci Monit
. 2019
;25
:1017
–23
. 4.
Yi
X
, Guo
W
, Shi
Q
, Yang
Y
, Zhang
W
, Chen
X
, et al. SIRT3-dependent mitochondrial dynamics remodeling contributes to oxidative stress-induced melanocyte degeneration in vitiligo
. Theranostics
. 2019
;9
(6
):1614
–33
. 5.
Wu
X
, Jin
S
, Yang
Y
, Lu
X
, Dai
X
, Xu
Z
, et al. Altered expression of ferroptosis markers and iron metabolism reveals a potential role of ferroptosis in vitiligo
. Pigment Cell Melanoma Res
. 2022
;35
(3
):328
–41
. 6.
Xuan
Y
, Yang
Y
, Xiang
L
, Zhang
C
. The role of oxidative stress in the pathogenesis of vitiligo: a culprit for melanocyte death
. Oxid Med Cell Longev
. 2022
;2022
:8498472
. 7.
Yang
M
, Li
X
, Li
H
, Zhang
X
, Liu
X
, Song
Y
. Baicalein inhibits RLS3-induced ferroptosis in melanocytes
. Biochem Biophys Res Commun
. 2021
;561
:65
–72
. 8.
Guo
R
, Li
L
, Su
J
, Li
S
, Duncan
SE
, Liu
Z
, et al. Pharmacological activity and mechanism of tanshinone IIA in related diseases
. Drug Des Devel Ther
. 2020
;14
:4735
–48
. 9.
Ansari
MA
, Khan
FB
, Safdari
HA
, Almatroudi
A
, Alzohairy
MA
, Safdari
M
, et al. Prospective therapeutic potential of Tanshinone IIA: an updated overview
. Pharmacol Res
. 2021
;164
:105364
. 10.
Zhang
D
, Wang
Y
, Li
G
, Zhang
B
. Tanshinone IIA alleviates vitiligo by suppressing AKT mediated CD8(+) T cells activation in a mouse model
. Dermatol Ther
. 2021
;34
(5
):e15086
. 11.
Zhong
H
, An
X
, Li
Y
, Cai
M
, Ahmad
O
, Shang
J
, et al. Sodium tanshinone IIA silate increases melanin synthesis by activating the MAPK and PKA pathways and protects melanocytes from H2O2-induced oxidative stress
. RSC Adv
. 2019
;9
(33
):18747
–57
. 12.
He
L
, Liu
YY
, Wang
K
, Li
C
, Zhang
W
, Li
ZZ
, et al. Tanshinone IIA protects human coronary artery endothelial cells from ferroptosis by activating the NRF2 pathway
. Biochem Biophys Res Commun
. 2021
;575
:1
–7
. 13.
Wang
TX
, Duan
KL
, Huang
ZX
, Xue
ZA
, Liang
JY
, Dang
Y
, et al. Tanshinone functions as a coenzyme that confers gain of function of NQO1 to suppress ferroptosis
. Life Sci Alliance
. 2023
;6
(1
):e202201667
. 14.
Tonelli
C
, Chio
IIC
, Tuveson
DA
. Transcriptional regulation by Nrf2
. Antioxid Redox Signal
. 2018
;29
(17
):1727
–45
. 15.
Saha
S
, Buttari
B
, Panieri
E
, Profumo
E
, Saso
L
. An overview of Nrf2 signaling pathway and its role in inflammation
. Molecules
. 2020
;25
(22
):5474
. 16.
Lin
X
, Meng
X
, Song
Z
, Lin
J
. Nuclear factor erythroid 2-related factor 2 (Nrf2) as a potential therapeutic target for vitiligo
. Arch Biochem Biophys
. 2020
;696
:108670
. 17.
Sorour
NE
, Abd El-Kareem
HM
, Ibrahim
AE
, Salem
RM
. Nuclear factor erythroid-2-related factor 2 gene polymorphisms in vitiligo
. J Clin Aesthet Dermatol
. 2021
;14
(6
):14
–7
.18.
Sun
X
, Ou
Z
, Chen
R
, Niu
X
, Chen
D
, Kang
R
, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
. Hepatology
. 2016
;63
(1
):173
–84
. 19.
Han
D
, Liu
W
, Li
G
, Liu
L
. Circ_PRKDC knockdown promotes skin wound healing by enhancing keratinocyte migration via miR-31/FBN1 axis
. J Mol Histol
. 2021
;52
(4
):681
–91
. 20.
Jiang
W
, Li
S
, Chen
X
, Zhang
W
, Chang
Y
, He
Y
, et al. Berberine protects immortalized line of human melanocytes from H2O2-induced oxidative stress via activation of Nrf2 and Mitf signaling pathway
. J Dermatol Sci
. 2019
;94
(1
):236
–43
. 21.
Rashighi
M
, Harris
JE
. Vitiligo pathogenesis and emerging treatments
. Dermatol Clin
. 2017
;35
(2
):257
–65
. 22.
Mou
Y
, Wang
J
, Wu
J
, He
D
, Zhang
C
, Duan
C
, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer
. J Hematol Oncol
. 2019
;12
(1
):34
. 23.
Wu
X
, Li
Y
, Zhang
S
, Zhou
X
. Ferroptosis as a novel therapeutic target for cardiovascular disease
. Theranostics
. 2021
;11
(7
):3052
–9
. 24.
Seibt
TM
, Proneth
B
, Conrad
M
. Role of GPX4 in ferroptosis and its pharmacological implication
. Free Radic Biol Med
. 2019
;133
:144
–52
. 25.
Xie
X
, Zhong
R
, Luo
L
, Lin
X
, Huang
L
, Huang
S
, et al. The infection characteristics and autophagy defect of dermal macrophages in STZ-induced diabetic rats skin wound Staphylococcus aureus infection model
. Immun Inflamm Dis
. 2021
;9
(4
):1428
–38
. 26.
Zhang
X
, Wang
Q
, Wang
X
, Chen
X
, Shao
M
, Zhang
Q
, et al. Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway
. Biomed Pharmacother
. 2019
;112
:108599
. 27.
Subedi
L
, Gaire
BP
. Tanshinone IIA: a phytochemical as a promising drug candidate for neurodegenerative diseases
. Pharmacol Res
. 2021
;169
:105661
. 28.
Guan
Z
, Chen
J
, Li
X
, Dong
N
. Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation
. Biosci Rep
. 2020
;40
(8
):BSR20201807
. 29.
Ni
H
, Ruan
G
, Sun
C
, Yang
X
, Miao
Z
, Li
J
, et al. Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis
. Environ Toxicol
. 2022
;37
(2
):192
–200
. 30.
Dodson
M
, Castro-Portuguez
R
, Zhang
DD
. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis
. Redox Biol
. 2019
;23
:101107
. 31.
Dong
H
, Qiang
Z
, Chai
D
, Peng
J
, Xia
Y
, Hu
R
, et al. Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1
. Aging
. 2020
;12
(13
):12943
–59
. 32.
Li
S
, Zheng
L
, Zhang
J
, Liu
X
, Wu
Z
. Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy
. Free Radic Biol Med
. 2021
;162
:435
–49
. 33.
Liang
R
, Zhao
Q
, Jian
G
, Cheng
D
, Wang
N
, Zhang
G
, et al. Tanshinone IIA attenuates contrast-induced nephropathy via Nrf2 activation in rats
. Cell Physiol Biochem
. 2018
;46
(6
):2616
–23
. 34.
Fu
K
, Feng
C
, Shao
L
, Mei
L
, Cao
R
. Tanshinone IIA exhibits anti-inflammatory and antioxidative effects in LPS-stimulated bovine endometrial epithelial cells by activating the Nrf2 signaling pathway
. Res Vet Sci
. 2021
;136
:220
–6
. 35.
Chen
J
, Yin
Z
, Yu
N
, Ou
S
, Wang
X
, Li
H
, et al. Tanshinone alleviates UVA-induced melanogenesis in melanocytes via the Nrf2-regulated antioxidant defense signaling pathway
. Curr Mol Med
. 2024
;24
(12
):1529
–39
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
